Sexually Transmitted Infection Prevalence Among Women at Risk for HIV Exposure Initiating Safer Conception Care in Rural, Southwestern Uganda.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
15
5
2020
medline:
20
4
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda. We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates. Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94). We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.
Sections du résumé
BACKGROUND
Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda.
METHODS
We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates.
RESULTS
Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94).
CONCLUSIONS
We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.
Identifiants
pubmed: 32404858
doi: 10.1097/OLQ.0000000000001197
pmc: PMC7363531
mid: NIHMS1590925
pii: 00007435-202008000-00014
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24-e28Subventions
Organisme : Doris Duke Charitable Foundation
ID : 2016094
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007433
Pays : United States
Références
Hum Reprod. 2010 Jul;25(7):1722-33
pubmed: 20410218
Bull World Health Organ. 2013 Mar 1;91(3):217-26
pubmed: 23476094
Sex Transm Dis. 2017 Mar;44(3):135-140
pubmed: 28178109
Lancet. 2016 Feb 6;387(10018):587-603
pubmed: 26794078
J Int AIDS Soc. 2015 Apr 24;18:19866
pubmed: 25912181
BMC Infect Dis. 2018 Oct 3;18(1):499
pubmed: 30285705
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Biom J. 2018 May;60(3):431-449
pubmed: 29292533
Sex Transm Dis. 2005 Jun;32(6):351-7
pubmed: 15912081
Bull World Health Organ. 2019 Aug 01;97(8):548-562P
pubmed: 31384073
AIDS Behav. 2018 Jun;22(6):1713-1724
pubmed: 28501964
Lancet. 2010 Apr 24;375(9724):1482-90
pubmed: 20223514
J Infect Dis. 2010 Jun 15;201 Suppl 2:S178-89
pubmed: 20524235
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Sex Transm Dis. 2013;2013:358402
pubmed: 26316957
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Sex Transm Dis. 2018 Dec;45(12):829-833
pubmed: 29944643